Skip to main content
ADMA BIOLOGICS, INC. logo

ADMA BIOLOGICS, INC. — Investor Relations & Filings

Ticker · ADMA ISIN · US0008991046 US Manufacturing
Filings indexed 962 across all filing types
Latest filing 2019-03-15 Director's Dealing
Country US United States of America
Listing US ADMA

About ADMA BIOLOGICS, INC.

https://www.admabiologics.com/

ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company that develops, manufactures, and commercializes specialty plasma-derived biologics. The company's portfolio features FDA-approved immune globulin (Ig) products for the treatment of immune-compromised patients and individuals at risk for certain infections. ADMA Biologics operates a vertically integrated manufacturing process for its specialty biologic products and utilizes a patented immunotechnology platform, which includes a proprietary microneutralization assay to measure neutralizing antibody levels in plasma. The company also offers contract manufacturing capabilities.

Recent filings

Filing Released Lang Actions
Director's Dealing 2019
Director's Dealing
2019-03-15 English
Director's Dealing 2019
Director's Dealing
2019-03-15 English
Director's Dealing 2019
Director's Dealing
2019-03-15 English
Director's Dealing 2019
Director's Dealing
2019-03-15 English
Annual Report 2018
Annual Report FY 2018
2019-03-13 English
Earnings Release 2019
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text specifically mentions Item 2.02 "Results of Operations and Financial Condition" and states that a press release announcing financial results for the year ended December 31, 2018, is furnished as an exhibit. The document itself does not contain detailed financial statements or comprehensive analysis but rather references a press release with financial results. The length is 3229 characters, which is relatively short and consistent with an announcement rather than a full report. According to the rules, such a document is best classified as an Earnings Release (ER) since it announces quarterly or annual financial results highlights, not the full Annual Report (10-K) or Interim Report (IR).
2019-03-13 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.